This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients
Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label
Patients who are willing to provide written informed consent prior to study enrollment
Patients under 12 years old
Patients with contraindication according to locally approved label of Jakavi®
Patients who receive or are going to receive any investigational medicine during the observation period.